Drug intelligence / Profile preview

ViraShield

Development stage: Unknown
Lead developer: AMH Biotech
Administration: Oral

Overview

ViraShield is a natural dietary supplement developed by AMH Bioteck (also known as AMH Biotech) to support the body's immune defense against viral threats, including SARS-CoV-2 (COVID-19), influenza, and general viral infections. Formulated by a team of molecular biologists and medicinal chemists, the product is positioned as an over-the-counter solution that combines research and natural ingredients to enhance immune resilience. Unlike traditional pharmaceutical antivirals that target specific viral enzymes or host receptors, ViraShield operates through a supportive nutraceutical mechanism designed to bolster the host's innate ability to combat pathogenic viruses.

Brand names: ViraShield
Other names: Vira Shield SupplementViraShield Formula

Beyond the preview

Go deeper on ViraShield.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViraShield.

Explore the full profile